Status and phase
Conditions
Treatments
About
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
670 participants in 2 patient groups
Loading...
Central trial contact
Siobhan Garbutt, PhD; Nicox Ophthalmics
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal